Pulmatrix Updates Financial Results and Merger Plans with Eos SENOLYTIX

Pulmatrix Financial Update and Merger Progress



Framingham, Massachusetts, November 17, 2026 – Pulmatrix, Inc., a biopharmaceutical company specializing in next-generation inhaled therapies, has revealed its third-quarter financial results for the year 2026 alongside significant updates on its merger with Eos SENOLYTIX. The merger is set to close by the end of the year, subject to certain approvals.

Merger with Eos SENOLYTIX


Pulmatrix's recent merger agreement with Eos SENOLYTIX, announced earlier in 2026, marks a pivotal moment for both companies. Eos SENOLYTIX is recognized for its innovative gerotherapeutic peptides developed to combat age-related disorders, utilizing the MitoXcel platform.
Peter Ludlum, Interim Chief Executive Officer of Pulmatrix, stated, "Our collaboration with Eos SENOLYTIX reflects our commitment to enhance our therapeutic offerings while simultaneously addressing unmet medical needs in aging populations. The effectiveness of our registration efforts ensures we're on track for a seamless merger process."

The merger agreement signifies that an entirely owned subsidiary of Pulmatrix will merge with Eos, creating a combined entity poised to drive advancements in both respiratory therapies and agents focused on mitochondrial dysfunction. A key development towards this merger was the SEC's approval of the registration statement related to the merger, as well as favorable shareholder votes.

Financial Overview


In terms of finances, Pulmatrix reported a research and development expense of just below $0.1 million for the three months ending September 30, 2026, which remains unchanged from the previous year. However, the general and administrative expenses saw a substantial increase to approximately $1.2 million, up from around $0.9 million in Q3 2025, primarily due to expenses incurred during the merger process.

As of September 30, 2026, the company maintained a cash balance of $1.4 million, along with $0.7 million in restricted cash—funds that may become available pending the merger's completion. Despite a decline from $4.1 million in cash at the end of 2025, Pulmatrix believes the operational efficiencies and careful prioritization allow it to sustain operations at least until the anticipated merger closure.

Advancements in Product Development


Pulmatrix is steadfast regarding its iSPERSE™ technology, designed for improved inhalation therapies. This platform has yielded promising results in various clinical trials. For instance, their iSPERSE™ formulation, PUR1900, now in Phase 3 trials in India for antifungal treatment, and PUR3100, designed for acute migraines, has obtained FDA's acceptance to advance into Phase 2 studies.

The company is looking into opportunities to license or monetize its clinical assets in the wake of ongoing strategic partnerships, especially considering its robust patent portfolio that has expanded significantly this year. With the financial stability gained through the merger, Pulmatrix is optimistic about its future trajectory.

Conclusion


The anticipated merger with Eos SENOLYTIX is expected to catalyze Pulmatrix's growth, allowing it to diversify and expand its therapeutic range while addressing significant health challenges. Stakeholders eagerly await further developments as these strategic initiatives unfold, marking a new chapter in Pulmatrix's commitment to advancing healthcare solutions. As the merger date nears, both companies are poised to take meaningful steps towards combining their innovative capabilities efficiently.

For further updates on Pulmatrix’s progress, visit their official site or stay tuned for future announcements.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.